Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ethnic differences in asthma and associated phenotypes: collaborative study on the genetics of asthma.

The Journal of allergy and clinical immunology·2001

Same author

Case report of venom immunotherapy for a patient with large local reactions.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2001

Same author

Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy.

The Journal of allergy and clinical immunology·2001

Same author

Insect sting allergy with negative venom skin test responses.

The Journal of allergy and clinical immunology·2001

Same author

Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s.

Journal of immunology (Baltimore, Md. : 1950)·2001

Same author

Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers.

The Journal of investigative dermatology·2000

Same journal

Corrigendum.

The Journal of allergy and clinical immunology·2026

Same journal

Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.

The Journal of allergy and clinical immunology·2026

Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026

Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026

Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026

Same journal

Maternal antibiotic exposure alters the newborn metabolomic profile and increases the risk of respiratory infections in offspring: a 13-year longitudinal birth cohort study.

The Journal of allergy and clinical immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Immunotherapy for cat asthma.

T E Van Metre¹, D G Marsh, N F Adkinson

¹Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

The Journal of Allergy and Clinical Immunology

|December 1, 1988

Summary

This summary is machine-generated.

Cat allergen immunotherapy significantly reduced allergic reactions in cat-asthma patients. This treatment was well-tolerated, decreasing skin and bronchial responses while increasing specific antibodies to cat allergens.

More Related Videos

Murine Model of Allergen Induced Asthma

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Acupuncture in a Rat Model of Asthma

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Related Experiment Videos

Last Updated: Jul 7, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Murine Model of Allergen Induced Asthma

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Acupuncture in a Rat Model of Asthma

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Area of Science:

Allergy and Immunology
Respiratory Medicine
Immunotherapy

Background:

Cat asthma affects numerous individuals, often triggered by hypersensitivity to cat allergens.
Current treatments focus on symptom management, with immunotherapy offering a potential disease-modifying approach.

Purpose of the Study:

To evaluate the efficacy and safety of immunotherapy using cat-hair and dander extract in patients with cat asthma.
To assess changes in bronchial reactivity, skin sensitivity, and specific antibody levels following immunotherapy.

Main Methods:

A double-blind, placebo-controlled study involving 22 cat-asthma patients highly sensitive to cats.
Patients were matched for allergen sensitivity and bronchial reactivity (methacholine PD20).
Immunotherapy involved escalating doses of cat-hair and dander extract, with assessments after one year.

Main Results:

Immunotherapy significantly decreased bronchial reactivity to cat extract (cat-extract PD20) and diminished skin test responses (STEPT).
Patients receiving immunotherapy showed increased IgE antibodies to cat extract and increased IgG antibodies to cat extract, Fel d I, and cat albumin.
No significant changes were observed in leukocyte histamine release (LHR) or bronchial reactivity to methacholine.

Conclusions:

Cat allergen immunotherapy is well-tolerated and effective in reducing allergic responses in cat-asthma patients.
The treatment leads to significant improvements in both clinical and immunological markers of cat allergy.
Immunotherapy represents a promising therapeutic strategy for managing cat-induced asthma.